Fletcher A P, Alkjaersig N K, Ghani F M, Tulevski V, Owens O
J Lab Clin Med. 1979 Jun;93(6):1054-65.
Two hundred twenty patients admitted to a Coronary Care Unit were studied by serial plasma fibrinogen chromatography--a method for quantification of HMWFCs, native fibrinogen, and other fibrinogen derivatives in plasma. Enhanced formation of fibrin (intravascular coagulation/thrombosis) is reflected by elevation of plasma HMWFC. One hundred ten patients suffering from documented acute myocardial infarction showed early, sharp elevation of plasma HMWFC (p less than 0.001 when compared to normal and cardiac control groups), a finding which persisted for 10 to 20 days after infarction. Forty-three of the patients did not receive anticoagulant therapy, and the others received either initial heparin, heparin plus warfarin, or werfarin therapy. Plasma fibrinogen chromatographic findings, days 1 to 5, did not differ between the anticoagulated and nonanticoagulated treatment groups, although there were minor differences in the data for days 6 to 10. The results demonstrate that patients with acute myocardial infarction develop a coagulopathy characterized by enhanced fibrin formation, which is influenced to only a minor degree by conventional dosage anticoagulant therapy.
对入住冠心病监护病房的220名患者进行了连续血浆纤维蛋白原色谱分析研究——这是一种定量检测血浆中高分子量纤维蛋白原成分（HMWFCs）、天然纤维蛋白原及其他纤维蛋白原衍生物的方法。血浆HMWFC升高反映了纤维蛋白形成增加（血管内凝血/血栓形成）。110名确诊为急性心肌梗死的患者血浆HMWFC早期急剧升高（与正常组和心脏对照组相比，p<0.001），这一现象在梗死后持续10至20天。其中43名患者未接受抗凝治疗，其余患者接受了初始肝素治疗、肝素加华法林治疗或华法林治疗。抗凝治疗组和未抗凝治疗组在第1至5天的血浆纤维蛋白原色谱分析结果无差异，尽管在第6至10天的数据存在细微差异。结果表明，急性心肌梗死患者会出现以纤维蛋白形成增加为特征的凝血病，传统剂量的抗凝治疗对其影响较小。
